The story has been updated to include comments from Qiagen's conference call this morning.

NEW YORK (GenomeWeb News) – Qiagen reported after the close of the market on Tuesday that revenues for its second quarter increased 3 percent year over year at a constant exchange rate.

The company also announced a new share buyback program of up to $100 million. Based on the closing price of its stock on July 29, that would represent approximately 5 million shares, Qiagen said.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.

A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.

An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.

In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.